At a glance
ClinicalIndex Comparison Record- ✓Type 2 diabetes mellitus diagnosed by fasting plasma glucose >126 mg/dL or 2-hour postload glucose >200 mg/dL on oral glucose tolerance test (confirmed by retest)
- ✓Age ≥40 years with history of cardiovascular disease (prior MI, stroke, coronary/peripheral/carotid revascularization, or angina)
- ✓Age ≥55 years with high cardiovascular risk, including existing CVD, subclinical disease, or ≥2 CVD risk factors (prior CVD history not required)
- ✓HbA1c 7.5-9% (if on multiple diabetes drugs) or 7.5-11% (if on fewer drugs)
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
In Brief
A Phase 3 clinical trial evaluating Anti-hyperglycemic Agents, Anti-hypertensive Agents, and 1 other intervention for Atherosclerosis and 6 related conditions. Completed, enrolled 10,251 participants across 7 sites in 2 countries.
Detailed Summary
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
Study Details
Timeline
Interventions
Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.